T3 Pharmaceuticals, a Swiss biotech company that promotes immuno-oncology with its bacteria-based protein delivery platform, closed its third round of financing of CHF 25 million. The financing was led by existing investors, including the Boehringer Ingelheim Venture Fund (BIVF), Reference Capital, Wille Finance and private investors, all of whom participated in the financing round. With this latest financing, T3 Pharma’s total financing has increased to CHF 40 million since the company was founded in 2015. T3 Pharma will use the funds primarily to advance its lead candidate, T3P-Y058-739, through clinical trials. The start of the phase 1/2 clinical trial on solid tumors is planned for early 2021.